Analysis of circulating tumour DNA (ctDNA) in blood samples provides a surrogate form of tumour biopsy (liquid biopsy) for determining EGFR and KRAS mutation status in patients with advanced-stage non-small-cell lung cancer. This approach obviates the need for a repeat biopsy, especially for the EGFR T790M mutation, which confers resistance to EGFR inhibition.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Circulating tumour cells and PD-L1-positive small extracellular vesicles: the liquid biopsy combination for prognostic information in patients with metastatic non-small cell lung cancer
British Journal of Cancer Open Access 16 November 2023
-
Statistical analysis of mutant allele frequency level of circulating cell-free DNA and blood cells in healthy individuals
Scientific Reports Open Access 08 August 2017
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Sacher, A. G. et al. Prospective validation of rapid plasma genotyping for the detection of EGFR and KRAS mutations in advanced lung cancer. JAMA Oncol. http://dx.doi.org/10.1001/jamaoncol.2016.0173 (2016).
Kalikaki, A. et al. Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC. Br. J. Cancer 99, 923–929 (2008).
Karachaliou, N. et al. Association of EGFR L858R mutation in circulating free DNA with survival in the EURTAC Trial. JAMA Oncol. 1, 149–157 (2015).
Doebele, R. C. et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin. Cancer Res. 18, 1472–1482 (2012).
Diaz, L. A. Jr et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 486, 537–540 (2012).
Rosell, R. et al. Screening for epidermal growth factor receptor mutations in lung cancer. N. Engl. J. Med. 361, 958–967 (2009).
Gautschi, O. et al. Origin and prognostic value of circulating KRAS mutations in lung cancer patients. Cancer Lett. 254, 265–273 (2007).
Schwarzenbach, H., Hoon, D. S. & Pantel, K. Cell-free nucleic acids as biomarkers in cancer patients. Nat. Rev. Cancer 11, 426–437 (2011).
Thress, K. S. et al. EGFR mutation detection in ctDNA from NSCLC patient plasma: a cross-platform comparison of leading technologies to support the clinical development of AZD9291. Lung Cancer 90, 509–515 (2015).
Niederst, M. J. et al. The allelic context of the C797S mutation acquired upon treatment with third generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies. Clin. Cancer Res. 21, 3924–3933 (2015).
Acknowledgements
The work of the authors is supported by grants from the La Caixa Foundation and Red Tematica de Investigacion Cooperativa en Cancer (RTICC; grant RD12/0036/0072).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Rosell, R., Karachaliou, N. Using ctDNA to track EGFR and KRAS mutations in advanced-stage disease. Nat Rev Clin Oncol 13, 401–402 (2016). https://doi.org/10.1038/nrclinonc.2016.83
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2016.83
This article is cited by
-
Circulating tumour cells and PD-L1-positive small extracellular vesicles: the liquid biopsy combination for prognostic information in patients with metastatic non-small cell lung cancer
British Journal of Cancer (2024)
-
Statistical analysis of mutant allele frequency level of circulating cell-free DNA and blood cells in healthy individuals
Scientific Reports (2017)